1. Academic Validation
  2. SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis

SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis

  • Dev Cell. 2024 May 17:S1534-5807(24)00296-X. doi: 10.1016/j.devcel.2024.04.023.
Peng-Cheng Yu 1 Dan Hou 2 Binhe Chang 2 Na Liu 3 Chun-Hui Xu 2 Xinchi Chen 2 Cheng-Long Hu 2 Ting Liu 4 Xiaoning Wang 5 Qunling Zhang 6 Ping Liu 2 Yilun Jiang 2 Ming-Yue Fei 2 Li-Juan Zong 2 Jia-Ying Zhang 2 Hui Liu 4 Bing-Yi Chen 2 Shu-Bei Chen 7 Yong Wang 2 Zi-Juan Li 2 Xiya Li 2 Chu-Han Deng 2 Yi-Yi Ren 2 Muying Zhao 2 Shiyu Jiang 6 Roujia Wang 8 Jiacheng Jin 8 Shaoxin Yang 9 Kai Xue 10 Jun Shi 9 Chun-Kang Chang 8 Shuhong Shen 4 Zhikai Wang 11 Peng-Cheng He 5 Zhu Chen 10 Sai-Juan Chen 10 Xiao-Jian Sun 12 Lan Wang 13
Affiliations

Affiliations

  • 1 CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • 2 CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
  • 3 Department of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • 4 Key Laboratory of Pediatric Hematology & Oncology of the Ministry of Health of China, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
  • 5 Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
  • 6 Department of Medical Oncology, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
  • 7 School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
  • 8 Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
  • 9 Department of Hematology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
  • 10 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • 11 MOE Key Laboratory for Membraneless Organelles and Cellular Dynamics, University of Science and Technology of China, Hefei 230027, China.
  • 12 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
  • 13 CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China. Electronic address: lwang@sinh.ac.cn.
Abstract

A significant variation in chromatin accessibility is an epigenetic feature of leukemia. The cause of this variation in leukemia, however, remains elusive. Here, we identify SMARCA5, a core ATPase of the imitation switch (ISWI) chromatin remodeling complex, as being responsible for aberrant chromatin accessibility in leukemia cells. We find that SMARCA5 is required to maintain aberrant chromatin accessibility for leukemogenesis and then promotes transcriptional activation of AKR1B1, an aldo/keto reductase, by recruiting transcription co-activator DDX5 and transcription factor SP1. Higher levels of AKR1B1 are associated with a poor prognosis in leukemia patients and promote leukemogenesis by reprogramming fructose metabolism. Moreover, pharmacological inhibition of AKR1B1 has been shown to have significant therapeutic effects in leukemia mice and leukemia patient cells. Thus, our findings link the aberrant chromatin state mediated by SMARCA5 to AKR1B1-mediated endogenous fructose metabolism reprogramming and shed light on the essential role of AKR1B1 in leukemogenesis, which may provide therapeutic strategies for leukemia.

Keywords

AKR1B1; DDX5; SMARCA5; SP1; leukemia.

Figures
Products
Inhibitors & Agonists
Other Products